Introduction
============

Metabolic syndrome predisposes individuals to diabetes and cardiovascular disease and affects over one-quarter of Americans and Canadians, making it an important public health concern ([@bib1], [@bib2]). Metabolic syndrome is now defined as the presence of any 3 of the following 5 risk factors: elevated waist circumference \[central obesity\], elevated TG (≥1.7 mmol/L), low HDL cholesterol (\<1.0 mmol/L for men, \<1.3 mmol/L for women) or drug treatment for low HDL cholesterol, elevated blood pressure (≥130/85 mm Hg) or antihypertensive drug treatment, or elevated fasting glucose (≥5.6 mmol/L) or drug treatment for elevated blood glucose ([@bib3]). Meanwhile, uric acid is commonly associated with gout, an inflammatory condition affecting 8.3 million Americans ([@bib4]). Further, hyperuricemia has been shown to be associated with components of metabolic syndrome, including hypertension and diabetes ([@bib5]--[@bib7]). Hyperuricemia is associated with obesity, excessive alcohol intake, and kidney failure ([@bib5]). Uric acid concentrations have increased recently and the prevalence of hyperuricemia in U.S. adults is estimated at 21.4% ([@bib4]). Proposed mechanisms of uric acid-mediated metabolic syndrome include the inhibition of endothelial NO leading to hypertension; inflammation and oxidative stress in adipocytes leading to insulin resistance; and increased endothelial and smooth muscle oxidative stress ([@bib6], [@bib7]).

Dietary factors are thought to be important modulators of serum uric acid. Worldwide fructose intake, particularly in the form of high fructose corn syrup, has paralleled the rise in metabolic syndrome and hyperuricemia ([@bib8]). High fructose consumption is associated with features of metabolic syndrome through an effect on uric acid ([@bib9], [@bib10]). Fructose metabolism can promote uric acid formation ([@bib7]). Once absorbed into the cell, unregulated phosphorylation of fructose by fructokinase leads to local ATP depletion and increased AMP production, which in turn increases uric acid ([@bib7]). Early acute human studies demonstrated elevated serum uric acid after fructose feeding ([@bib11]). Evidence from longer term fructose feeding trials ([@bib12]--[@bib27]) and observational studies ([@bib10], [@bib28]--[@bib32]), however, have shown mixed results.

There are currently no recommendations addressing the effect of dietary fructose intake on uric acid and the risk of gout or metabolic syndrome. Various health agencies, including the American Diabetes Association, the European Association for the Study of Diabetes, and the AHA, have discouraged high intakes of fructose based on adverse affects on serum lipids ([@bib33]--[@bib35]). To evaluate the need for additional clinical evidence regarding the effects of fructose consumption on uric acid in humans, we conducted a systematic review and meta-analysis of controlled feeding trials to assess the effect of fructose on uric acid.

Methods
=======

This systematic review and meta-analysis followed a similar methodological approach as Sievenpiper et al. ([@bib36]). We followed the Cochrane Handbook for Systematic Reviews of Interventions for the planning and conduct of this meta-analysis ([@bib37]). The reporting followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines ([@bib38], [@bib39]).

### Study selection.

We conducted a search of MEDLINE (1948 through August 19, 2011), EMBASE (1974 through August 19, 2011), and the Cochrane Central Register of Controlled Trials database (1950 through August 19, 2011) using the search terms: fructose AND (uric acid OR urate). Inclusion criteria is listed in **Supplemental Table 1**.

### Data extraction.

Three reviewers (D.W., V.H., L.C.) independently extracted the following study characteristics: design (parallel or crossover), randomization, blinding, sample size, participant characteristics (age, sex, BMI, and diabetes status), fructose form (solid, liquid, or mixed), dose, control reference carbohydrates (sucrose, starch, glucose), follow-up, and the macronutrient profile of the background diet. The quality of each study was assessed by each reviewer using the Heyland methodological quality score (MQS)[^13^](#fn5){ref-type="fn"} ([@bib40]), which assigns a score from 0 to 1 or 0 to 2 in 9 categories of quality related to study design, sampling procedures, and interventions for a total of 13 points. Disagreements were reconciled by consensus through discussion with another investigator (J.L.S.). The fasting serum uric acid concentration (mean ± SD) was extracted as the main endpoint. All trials reported end differences. We calculated missing SD values from available statistics using standard formulae ([@bib37]). Where these data were not reported preventing calculation, we imputed SD values using a pooled correlation coefficient derived from a meta-analysis of correlation coefficients from those trials reporting sufficient data. We derived correlation coefficients for individual trials according to a standard formula ([@bib37], [@bib41]). We then input these values into the meta-analysis as transformed Z-scores ± SE, from which we derived the pooled correlation coefficient. If SD coefficients still could not be imputed, then we derived the missing SD from the pooled SD imputed for the other trials ([@bib42]).

### Statistical analyses.

Data were analyzed using Review Manager (RevMan) version 5.0.25 (The Nordic Cochrane Centre, The Cochrane Collaboration). Separate pooled analyses for isocaloric and hypercaloric fructose feeding trials were conducted using the Generic Inverse Variance method using random effects models. Analyses were stratified by diabetes and nondiabetes. The outcome studied was end differences in serum uric acid. Potential sources of methodological heterogeneity were investigated by sensitivity analyses and a priori subgroup analyses, investigating the effect of comparator (starch, sucrose, glucose\]) fructose format (fluid, mixed, solid), dose \[Canadian Diabetes Association thresholds: ≤60 or \>60 g/d ([@bib43])\], follow-up (≤4 wk, \>4 wk), study quality \[Heyland MQS \<8, ≥8 ([@bib40])\], randomization, and study design (parallel or crossover). Meta-regressions were performed to assess the significance of subgroup effects (STATA 11.2). Publication bias was investigated by visual inspection of funnel plots and formally tested using Begg ([@bib44]) and Egger ([@bib45]) tests.

Results
=======

### Search results.

The systematic search and selection of the literature is outlined (**Supplemental Fig. 1**). A total of 375 reports were identified as eligible from the initial search, of which 340 reports were excluded based on the title or abstract. The remaining 35 reports were retrieved and reviewed, whereas a further 19 were excluded. A total of 16 met the eligibility criteria and were included in this meta-analysis. These 16 reports contained 18 isocaloric trials ([@bib12]--[@bib21], [@bib23]--[@bib27]) and 3 hypercaloric trials ([@bib22], [@bib23]) and one of the reports contained both an isocaloric and hypercaloric trial ([@bib23]).

### Trial characteristics.

Trial characteristics are shown in [**Table 1**](#tbl1){ref-type="table"}. Nine of the isocaloric trials were in 119 prediabetic and diabetic participants with 12 comparison arms and 9 of the isocaloric trials were in 271 nondiabetic participants with 8 comparison arms. The 3 hypercaloric trials were in 35 nondiabetic participants with 3 comparison arms. The mean age of participants was 42.6 y old (23--62 y old) in the isocaloric trials and 24.4 y old (24--24.6 y old) in the hypercaloric trials. Mean baseline uric acid was 317 *μ*mol/L (232--398 *μ*mol/L) in isocaloric trials and 312 *μ*mol/L (300--322 *μ*mol/L) in hypercaloric trials. Eight (44%) isocaloric trials and all 3 hypercaloric trials were randomized. Twelve (67%) isocaloric and all 3 hypercaloric trials used crossover designs. Starch (11 trial arms), sucrose (6 trial arms), or glucose (4 trial arms) were used as the comparator-carbohydrate in the isocaloric trials, whereas weight-maintaining control diets were used as the comparator in the hypercaloric trials. Fructose was administered in liquid, solid, or mixed formats at a mean dose of 94 g/d \[25--213 g/d or 5--33% energy (E)\] in the isocaloric trials and 215 g/d (213--219 g/d or +35% excess E) in the hypercaloric trials. Thirteen (72%) of the isocaloric trials and all 3 of the hypercaloric trials exceeded the dose threshold of 60 g/d proposed by the Canadian Diabetes Association ([@bib13], [@bib15]--[@bib17], [@bib19], [@bib20], [@bib22], [@bib23], [@bib26]). Nine (50%) isocaloric and all 3 hypercaloric trials used metabolically controlled designs. Background diets in the isocaloric and hypercaloric trials provided a wide range of macronutrient profiles. Isocaloric trial diets consisted of 43--92% E carbohydrate, 0--42% E fat, and 8--20% E protein. All hypercaloric trial diets consisted of 55% E carbohydrate, 30% E fat, and 15% E protein. The mean follow-up was 14.4 wk (1--95 wk) in the isocaloric trials, whereas all 3 hypercaloric trials lasted 1 wk. The Heyland MQS in the isocaloric trials ranged from 4 to 8 with 9 trials (50%) considered to be of higher quality (MQS ≥8). All hypercaloric trials were of higher quality with an MQS score of 8.

###### 

Characteristics of included trials

  Study                      Participants[^1^](#tblfn1){ref-type="table-fn"}   Age[^2^](#tblfn2){ref-type="table-fn"}   Baseline plasma uric acid[^3^](#tblfn3){ref-type="table-fn"}   Design[^4^](#tblfn4){ref-type="table-fn"}   Setting      Feeding control[^5^](#tblfn5){ref-type="table-fn"}   Randomization   Fructose dose[^6^](#tblfn6){ref-type="table-fn"}   Fructose form[^7^](#tblfn7){ref-type="table-fn"}   Comparator[^8^](#tblfn8){ref-type="table-fn"}   Diet energy CHO:fat:protein   Follow-up   MQS[^9^](#tblfn9){ref-type="table-fn"}
  -------------------------- ------------------------------------------------- ---------------------------------------- -------------------------------------------------------------- ------------------------------------------- ------------ ---------------------------------------------------- --------------- -------------------------------------------------- -------------------------------------------------- ----------------------------------------------- ----------------------------- ----------- ----------------------------------------
                             *n*                                               *y*                                      *μmol*/*L*                                                                                                                                                                                   *g/d (%E)*                                                                                                                                                                          *wk*        
  Isocaloric trials                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
   No diabetes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    Crapo ([@bib15])         11 N; 4M, 7F                                      39.5 ± 11.4                              339 ± 98.6                                                     C                                           IP, USA      Supp                                                 No              \~81 (13.2)                                        MX                                                 Sucrose                                         55:30:15                      2           7
    Forster ([@bib17])       6 N; 4M, 2F                                       23 (20--26)                              309 ± 77                                                       C                                           IP, GER      Met                                                  No              162 (33)                                           MX                                                 Glucose                                         92:00:08                      2.9         7
    Hallfrisch ([@bib19])    12 N; 12M, 0F                                     39.8 ± 8.3                               324 ± 82.3                                                     P                                           IP/OP, USA   Met                                                  No              \~101 (15)                                         SO                                                 Starch                                          43:42:15                      5           7
                             12 HI; 12M, 0F                                    39.5 ± 7.3                               371 ± 82                                                       P                                           IP/OP, USA   Met                                                  No              \~101 (15)                                         SO                                                 Starch                                          43:42:15                      5           7
    Huttunen ([@bib20])      68 N; 35 fructose, 33 sucrose                     27.5 ± 7.0                               320 ± 57.4                                                     P                                           OP, FIN      Supp                                                 No              69.1                                               MX                                                 Sucrose                                         ---                           95          5
    Koh ([@bib21])           9 N; 3M, 6F                                       50 ± 15                                  333 ± 53.5                                                     C                                           IP/OP, USA   PM                                                   No              \~78.5 (15)                                        MX                                                 Glucose                                         52:32:16                      4           8
    Madero ([@bib27])        109 N; 7M, 102F                                   38.8 ± 8.8                               329 ± 8.3                                                      P                                           OP, MEX      Supp                                                 Yes             \~60 (13)                                          MX                                                 Starch                                          55:30:15                      6           6
    Ngo Sock ([@bib23])      11 N; 11M, 0F                                     24.6 ± 2.0                               330 ± 29.8                                                     C                                           OP, SUI      Met                                                  Yes             \~213 (26)                                         LQ                                                 Glucose                                         55:30:15                      1           8
    Reiser ([@bib26])        11 N; 11M, 0F; 10 HI; 10M, 0F                     43.5 (23--64)                            312 ± 82.3                                                     C                                           OP, USA      Met                                                  No              167 (20)                                           MX                                                 Starch                                          51:36:13                      5           4
   Diabetes/prediabetes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    Anderson ([@bib12])      14 DM2; 14M, 0F                                   60 ± 4                                   360 ± 82.3                                                     C                                           OP, USA      PM                                                   No              \~55 (12)                                          MX                                                 Starch                                          55:25:20                      23          8
    Bantle ([@bib13])        12 DM1; 6M, 6F; 12 DM2; 5M, 7F                    62 (36--80)                              244 ± 82.3                                                     C                                           IP/OP, USA   Met                                                  Yes             \~136.5 (21)                                       MX                                                 Starch                                          55:30:15                      1.1         8
                             12 DM1; 6M, 6F; 12 DM2; 5M, 7F                    62 (40--72)                              250 ± 82.3                                                     C                                           IP/OP, USA   Met                                                  Yes             \~136.5 (21)                                       MX                                                 Sucrose                                         55:30:15                      1.1         8
    Blayo ([@bib14])         11 DM1; 3 DM2                                     46.9 ± 13.1                              232 ± 82.3                                                     P                                           OP, FRA      Supp                                                 Yes             \~25 (5)                                           MX                                                 Starch                                          55:30:15                      52          7
                             8 DM1; 4 DM2                                      46.9 ± 13.1                              244 ± 82.3                                                     P                                           OP, FRA      Supp                                                 Yes             \~25 (5)                                           MX                                                 Sucrose                                         55:30:15                      52          7
    Crapo ([@bib16])         7 DM2; 3M, 4F                                     50.9 ± 8.4                               357 ± 158                                                      C                                           IP, USA      Met                                                  No              \~97.5 (13.2)                                      MX                                                 Sucrose                                         55:30:15                      2           7
    Grigo resco ([@bib18])   8 DM2; 5M, 3F                                     40 ± 6.9                                 354 ± 102                                                      C                                           OP, FRA      Supp                                                 Yes             30 (8)                                             LQ                                                 Starch                                          50:30:20                      8           8
    Koh ([@bib21])           9 prediabetes; 3M, 6F                             50 ± 15                                  398 ± 35.7                                                     C                                           OP, FRA      PM                                                   No              \~78.5 (15)                                        MX                                                 Glucose                                         52:32:16                      4           8
    Osei ([@bib24])          13 DM2; 5M, 8F                                    54 ± 10.8                                274 ± 111                                                      C                                           OP, FRA      Met                                                  Yes             60 (7.5)                                           MX                                                 Starch                                          55:35:15                      26          8
    Osei ([@bib25])          18 DM2; 3M, 15F                                   57 ± 3.0                                 340 ± 144                                                      P                                           O, USA       Supp                                                 Yes             60 (10)                                            MX                                                 Starch                                          55:35:15                      12          8
  Hypercaloric trials                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
   No diabetes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    Le ([@bib22])            8 N; 8M, 0F                                       24.7 ± 5.2                               300 ± 22.6                                                     C                                           OP, SUI      Met                                                  Yes             \~213 (+35)                                        LQ                                                 Diet alone                                      55:30:15                      1           8
                             16 OffDM; 16M, 0F                                 24 ± 2.7                                 322 ± 20.0                                                     C                                           OP, SUI      Met                                                  Yes             \~219 (+35)                                        LQ                                                 Diet alone                                      55:30:15                      1           8
    Ngo Sock ([@bib23])      11 N; 11M, 0F                                     24.6 ± 2.0                               313 ± 29.8                                                     C                                           OP, SUI      Met                                                  Yes             \~213 (+35)                                        LQ                                                 Diet alone                                      55:30:15                      1           8

C, crossover; CHO, carbohydrate; DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus; E, energy; F, female; Fin, Finland; Fra, France; Ger, Germany; HI, hyperinsulinemic; IP, inpatient; LQ, liquid; M, male; Met, metabolic; Mex, Mexico; MQS, methodological quality score, MX, mixed; N, normal; OffDM, offspring of type 2 diabetes mellitus; OP, outpatient; P, parallel; PM, partial metabolic; SUI, Switzerland; Supp, supplement; SO, solid; USA, United States.

Values are mean ± SD or mean (range).

Baseline or control treatment (comparator) concentrations are mean ± SD.

Designs were either C or P.

Met feeding control represents the provision of all meals, snacks, and study supplements (test sugars and foods) consumed during the study under controlled conditions. PM feeding control represents the provision of some meals and snacks and all study supplements (test sugars and foods) consumed during the study under controlled conditions. Supp feeding control represents the provision of study supplements.

Doses were administered on a g/d, percentage energy, or g/kg body weight basis. Doses preceded by approximate symbol represent average doses calculated based on the average reported energy intake or weight of participants. If these data were not available, then the average dose was based on a 2000-kcal intake preceded by approximate symbol represent average doses.

Fructose was provided in 1 of 3 forms: LQ form, where all or most of the fructose was provided as beverages or crystalline fructose to be added to beverages; SO form, where fructose was provided as solid foods (fruit in the one case); or MX form, where all or most of the fructose was provided as a mix of beverages, solid foods (not fruit), and/or crystalline fructose.

Comparator refers to the reference carbohydrate (starch, sucrose, or glucose) in the isocaloric trials and diet alone (weight maintaining, background diet) in the hypercaloric trials. Fructose was exchanged for the reference carbohydrate providing an energy matched comparison in the isocaloric trials, whereas it was added to the diet alone providing excess energy relative to the diet alone in the hypercaloric trials.

Study quality was assessed by the Heyland MQS. Trials scored ≥8 were considered to be of higher quality.

### Isocaloric feeding trials.

The effect of fructose in isocaloric exchange for other carbohydrate on uric acid was not significant in prediabetic/diabetic participants mean difference (MD) = −4.09 (95% CI: −23.7, 15.6)\] and nondiabetic participants \[MD = 1.28 (95% CI: −6.65, 9.22)\] ([**Fig. 1**](#fig1){ref-type="fig"}). The lack of effect was found consistently across trials without any evidence of inter-study heterogeneity (*I*^2^ = 0% in both groups). Systematic removal of trials during sensitivity analyses did not alter the conclusions. There was no significant effect in any of the a prioi subgroups and no significant evidence of heterogeneity ([**Fig. 2**](#fig2){ref-type="fig"}).

![Forest plots of feeding trials investigating the effect of isocaloric exchange of fructose for carbohydrate on uric acid in people with and without diabetes. Three pooled effect estimates (*diamonds*) are shown: one each for trials in individuals with diabetes, no diabetes, and their combination. Paired analyses were applied to all crossover trials. Data are for weighted MD with 95% CI in uric acid (*μ*mol/L). Data are expressed as weighted MD with 95% CI using generic inverse variance random effects models. Inter-study heterogeneity was tested by Cochrane's Q statistic (chi-square) at a significance level of *P* \< 0.10 and quantified by I^2^, where I^2^ ≥ 50% is considered to be evidence of substantial heterogeneity and ≥75%, considerable heterogeneity. CHO, any carbohydrate comparator; DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus; IGT, impaired glucose tolerance; HI, hyperinsulemia; MD, mean difference; N, normal.](nut14200916fig1){#fig1}

![Subgroup analyses in the isocaloric feeding trials investigating the effect of isocaloric exchange of fructose for carbohydrate on uric acid in people with and without diabetes. Points for each subgroup level are the pooled effect estimates expressed as weighted MD with 95%CI using generic inverse variance random effect models. The dashed line represents the pooled effect estimate for the total analysis. CHO, any carbohydrate comparator; MD, mean difference.](nut14200916fig2){#fig2}

### Hypercaloric feeding trials.

There was a significant effect of hypercaloric (+35% E) fructose on serum uric acid in participants without diabetes ([**Fig. 3**](#fig3){ref-type="fig"}). A large uric acid-raising effect \[MD = 31.0 (95% CI: 15.4, 46.5); *P* \< 0.05\] of hypercaloric (+35% E) fructose was seen without any evidence of inter-study heterogeneity (*I*^2^ = 0%; *P* = 0.97). A priori subgroup analyses were not conducted owing to an insufficient number of trials.

![Forest plots of feeding trials investigating the effect of hypercaloric fructose feeding on serum uric acid under hypercaloric conditions, where a control diet was supplemented with excess energy from fructose, in people without diabetes. Data are for weighted MD with 95% CI in uric acid (*μ*mol/L). Data are expressed as weighted MD with 95% CI using generic inverse variance random effects models. Inter-study heterogeneity was tested by Cochrane's Q statistic (chi-square) at a significance level of *P* \< 0.10 and quantified by I^2^, where I^2^ ≥ 50% is considered to be evidence of substantial heterogeneity and ≥75%, considerable heterogeneity. CHO, any carbohydrate comparator; MD, mean difference; N, normal healthy participants; ODM2, offspring of type 2 diabetes mellitus.](nut14200916fig3){#fig3}

### Publication bias.

Funnel plots were inspected for the presence of publication bias ([**Fig. 4**](#fig4){ref-type="fig"}). There was a suggestion of funnel plot asymmetry with a lack of small trials favoring a uric-acid raising effect of fructose; however, neither Egger nor Begg tests provided sufficient evidence of publication bias for uric acid (Egger test, *P* = 0.95; Begg test, *P* = 0.14).

![Funnel plots for the effect of fructose in isocaloric exchange for other carbohydrate on uric acid. The dashed lines represent the pooled effect estimate expressed as a MD. The solid fitted lines represent Egger regression test for funnel-plot asymmetry. MD, mean difference.](nut14200916fig4){#fig4}

Discussion
==========

The present pooled analyses of 21 controlled feeding trials in 425 prediabetic/diabetic and nondiabetic participants demonstrate that the uric acid response to fructose feeding differs between isocaloric and hypercaloric feeding conditions. Isocaloric fructose intake did not raise uric acid, whereas hypercaloric fructose intake did. The mean increase in the hypercaloric trials was 31.0 *μ*mol/L.

The clinical and practical importance of the increase in uric acid in the hypercaloric trials is unclear. The 3 hypercaloric trials in this meta-analysis fed fructose at 35% excess E (852--876 kcal/d or 213--219 g/d) in fluid form in nondiabetic males for 1 wk, a level of exposure that is more than double the 95th percentile (87 g/d) of fructose intake in the US ([@bib46]). At these tremendous doses, the resulting 31.0-*μ*mol/L increase in uric acid has the potential to place many individuals at risk of hyperuricemia (\>416 *μ*mol/L in men or \>339 *μ*mol/L in women), where the mean serum urate concentrations in U.S. adults are 365 *μ*mol/L in men and 290 *μ*mol/L in women ([@bib4]). Extreme fructose doses inducing hyperuricemia have also been studied in the past. Perez-Pozo et al. ([@bib10]) conducted a randomized, 2-wk crossover trial in which participants were randomized to either allopurinol, a xanthine oxidase inhibitor which inhibits the production of uric acid, or placebo while consuming 200 g/d of fructose for 2 wk. Allopurinol was shown to decrease the fructose-induced rise in uric acid by 65 *μ*mol/L. Although this increase was reported under weight-maintaining conditions, the evidence from observational studies suggests that an excess of energy may be a prerequisite for a sustainable uric acid-increasing effect of fructose. In models not adjusted for total energy or carbohydrate intake, high fructose intake increased uric acid in the NHANES III ([@bib32]); however, in energy- and nonfructose carbohydrate-adjusted models, no effect of total fructose was found on either uric acid concentrations or risk of gout in NHANES 1999--2004 ([@bib32]). Although these data taken together with our findings highlight possible confounding from excess energy at high doses, the small number of trials in our hypercaloric analysis limits the confidence in our estimates.

In the isocaloric setting, there was no effect of fructose substitution for other carbohydrate on uric acid concentrations. This lack of effect contradicts data from the Health Professionals Follow-up study that found that sweetened soft drink intake (equivalent to \~ ≥100 g/d of fructose as high fructose corn syrup) was associated with a 29.1-*μ*mol/L increase in uric acid concentrations (29). Similarly, an analysis of NHANES III found that isocaloric substitution of sugar-sweetened beverages (equivalent to \~≥16% E as fructose) for other energy was associated with a 25.0-*μ*mol/L increase in uric acid and a multivariate OR of 1.82 for hyperuricemia ([@bib29]). The reason for the discordance between these observational data and our meta-analysis of controlled feeding trials is unclear. It is possible that there may be a threshold for fructose-mediated ATP depletion/AMP production, which is thought to lead to increased uric acid concentrations. The mean fructose dose in the isocaloric trials (93.4 g/d) was below the level of exposure associated with higher uric acid concentrations in the observational studies, which may also have incompletely adjusted for energy compensation. It was also well below the mean dose used in our included hypercaloric trials (215 g/d) used to induce higher uric acid concentrations and the animal models (60% E as fructose, which is equivalent to 300 g/d on a 2000-kcal diet) used to elucidate the mechanism of fructose-induced uric acid production ([@bib9]). A fructose dose threshold has been observed in clinical trials, below which the effects on other metabolic biomarkers are lost, e.g., ≤60 g/d in type 2 diabetes ([@bib36]) and \<100 g/d across all subject types ([@bib47]) for TG. Additionally, there is evidence of fructose intolerance and incomplete absorption at higher doses and concentrations, further confounding results from trials at high doses ([@bib48]). Population-level intakes of fructose, where the 50th percentile of fructose intake in the US is 49 g/d ([@bib46]), may be unlikely to elicit this mechanism in a clinically significant way. Both dose alone and dose in relation to excess energy, therefore, are important considerations in assessing adverse effects of fructose on uric acid.

The strength of the present analyses is the lack of both statistical heterogeneity and clinical heterogeneity. Neither stratification of the data nor a priori subgroup analyses altered the significance of the effect estimates or heterogeneity. The lack of an effect of fructose in isocaloric exchange for carbohydrate on uric acid was robust to stratification by diabetes status. It was also not modified by dose at a lower threshold (≤ or \>60 g/d), comparator (starch, sucrose, and glucose), follow-up (\< or ≥4 wk), design (crossover, parallel), study quality (MQS ≥ or \<8), randomization (yes, no), or fructose form (solid, liquid, mixed). Although not tested formally in subgroup analyses, composition of the background diet in the trials also did not appear to have an effect. One of the included isocaloric trials, Forster et al. ([@bib17]), had a background diet devoid of fat. This study was included, because it met all eligibility criteria. Removal of this trial during sensitivity analyses did not alter the conclusions, although this trial should be interpreted cautiously. The consistency across these different trial conditions helps to strengthen the generalizability of our conclusions.

Our analyses, nevertheless, have several limitations. First, our literature search would not have identified trials that measured uric acid and displayed uric acid data but was only discussed within a table or figure. Second, the hypercaloric studies recruited only men; previous studies have shown both sex and hormone effects on uric acid concentrations. Men generally have higher concentrations of uric acid than women and hormones play a role. Estrogen can reduce uric acid concentrations, mitigating many of the metabolic effects of uric acid ([@bib49]), whereas testosterone has been associated with increased uric acid ([@bib50]). Although the data support increased uric acid concentrations in men, we could not determine from the existing data the effects of hypercaloric fructose on women. Third, only 5 of the included isocaloric trials and none of the hypercaloric trials were longer than 12 wk. Although we found no evidence of effect according to follow-up, it is unclear whether the lack of effect of isocaloric fructose exchange for other carbohydrates on uric acid would be sustainable over the long term. It is also unclear whether isocaloric exchange conditions can be maintained over the long term. Longer-term trials would be helpful in separating out the short-term from the longer-term effects of fructose. Fourth, study quality was poor (MQS \<8) in 50% of the included trials. Complicating this issue was the incomplete reporting in many publications requiring a fair degree of imputations (7/18 trials required imputations). There was, however, no effect (*P* = 0.97) of MQS (\<8 vs. ≥8) in subgroup analyses. Although the use of a quality scoring method, such as the MQS, may have been inadequate ([@bib51]), the consistent lack of effect of all a priori subgroups ([Fig. 2](#fig2){ref-type="fig"}) supports the lack of a uric acid--raising effect (*P* \> 0.2 for all comparisons) of isocaloric fructose exchange for other carbohydrates. Fifth, only two-thirds of the isocaloric trials used crossover designs. However, Lathyris et al. ([@bib52]) performed a systematic review of Cochrane Reviews and found generally good agreement between parallel and crossover trials. Finally, publication bias was a possibility in both the isocaloric and hypercaloric trials. Visual inspection of funnel plots for both sets of trials along with Egger or Begg tests found limited evidence of funnel plot asymmetry and publication bias.

In conclusion, our work suggests that contrary to concerns, isocaloric fructose exchange for other sources of carbohydrate does not raise uric acid concentrations and this lack of effect holds across different experimental conditions. These conclusions, however, are limited by the short follow-up of the majority of trials and poor quality of one-half of the trials included in the meta-analysis. On the other hand, high fructose intake (213--219 g/d) under hypercaloric feeding conditions (+35% E) does raise serum uric acid concentrations, although confounding from excess energy cannot be ruled out in these trials. These data highlight the need for larger and longer fructose feeding trials conducted under free-living conditions to assess whether fructose consumption leads to excess energy intake and whether in turn the effects on uric acid are dependent on excess energy.
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